CDKN2A and pancreatic neoplasm: The AGA recommends initiating surveillance for pancreatic cancer in patients with a PRSS1 mutation and a CDKN2A mutation at the age of 40 years, which is similar to that by CAPS and the ASGE [16,77,78].